复发性多发性骨髓瘤-话题@MedSci

#复发性多发性骨髓瘤#

8篇内容 | 756人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1718341, encodeId=90761e18341c9, content=<a href='/topic/show?id=5a014253400' target=_blank style='color:#2F92EE;'>#复发性多发性骨髓瘤#</a>, objectTitle=Haematologica：Isatuximab 加卡非佐米和地塞米松与卡非佐米和地塞米松在肾功能不全的复发性多发性骨髓瘤患者中的比较, objectType=article, longId=292200, objectId=8c42292200d9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8c42292200d9, replyNumber=0, likeNumber=43, createdTime=2022-08-04, rootId=0, userName=meichuangyi, userId=ab3732554119, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8c42292200d9, moduleTitle=Haematologica：Isatuximab 加卡非佐米和地塞米松与卡非佐米和地塞米松在肾功能不全的复发性多发性骨髓瘤患者中的比较, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8c42292200d9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1718340, encodeId=71141e183403b, content=<a href='/topic/show?id=5a014253400' target=_blank style='color:#2F92EE;'>#复发性多发性骨髓瘤#</a>, objectTitle=NEJM：Ide-cel治疗复发性多发性骨髓瘤患者II期临床获得成功, objectType=article, longId=207800, objectId=df3320e8001b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=df3320e8001b, replyNumber=0, likeNumber=42, createdTime=2021-07-15, rootId=0, userName=meichuangyi, userId=ab3732554119, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=df3320e8001b, moduleTitle=NEJM：Ide-cel治疗复发性多发性骨髓瘤患者II期临床获得成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=df3320e8001b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1718339, encodeId=ec051e18339ab, content=<a href='/topic/show?id=5a014253400' target=_blank style='color:#2F92EE;'>#复发性多发性骨髓瘤#</a>, objectTitle=CHMP建议批准Sarclisa（isatuximab）与卡非佐米和地塞米松联合治疗复发性多发性骨髓瘤, objectType=article, longId=207705, objectId=73c620e7058a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=73c620e7058a, replyNumber=0, likeNumber=39, createdTime=2022-02-02, rootId=0, userName=meichuangyi, userId=ab3732554119, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=73c620e7058a, moduleTitle=CHMP建议批准Sarclisa（isatuximab）与卡非佐米和地塞米松联合治疗复发性多发性骨髓瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=73c620e7058a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1718338, encodeId=a2301e183382a, content=<a href='/topic/show?id=5a014253400' target=_blank style='color:#2F92EE;'>#复发性多发性骨髓瘤#</a>, objectTitle=Blood：pomalidomide、bortezomib和dexamethasone联合治疗复发性多发性骨髓瘤的很大耐受剂量、疗效和安全性。, objectType=article, longId=104924, objectId=e6b910492475, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e6b910492475, replyNumber=0, likeNumber=36, createdTime=2018-05-15, rootId=0, userName=meichuangyi, userId=ab3732554119, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e6b910492475, moduleTitle=Blood：pomalidomide、bortezomib和dexamethasone联合治疗复发性多发性骨髓瘤的很大耐受剂量、疗效和安全性。, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e6b910492475)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1718337, encodeId=c22d1e1833761, content=<a href='/topic/show?id=5a014253400' target=_blank style='color:#2F92EE;'>#复发性多发性骨髓瘤#</a>, objectTitle=专家解读：国际骨髓瘤工作组复发性多发性骨髓瘤处理推荐, objectType=article, longId=72504, objectId=2621e250466, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2621e250466, replyNumber=0, likeNumber=32, createdTime=2016-12-11, rootId=0, userName=meichuangyi, userId=ab3732554119, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2621e250466, moduleTitle=专家解读：国际骨髓瘤工作组复发性多发性骨髓瘤处理推荐, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2621e250466)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1718336, encodeId=d4351e1833680, content=<a href='/topic/show?id=5a014253400' target=_blank style='color:#2F92EE;'>#复发性多发性骨髓瘤#</a>, objectTitle=Lancet Haematology：复发性多发性骨髓瘤：Elotuzumab有良好的安全性和疗效性, objectType=article, longId=58894, objectId=8c0b5889437, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8c0b5889437, replyNumber=0, likeNumber=22, createdTime=2016-10-09, rootId=0, userName=meichuangyi, userId=ab3732554119, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8c0b5889437, moduleTitle=Lancet Haematology：复发性多发性骨髓瘤：Elotuzumab有良好的安全性和疗效性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8c0b5889437)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1718334, encodeId=7bbc1e183340c, content=<a href='/topic/show?id=5a014253400' target=_blank style='color:#2F92EE;'>#复发性多发性骨髓瘤#</a>, objectTitle=NEJM：卡非佐米+来那度胺+地塞米松治疗复发性多发性骨髓瘤：风险or受益？, objectType=article, longId=43820, objectId=b8bd43820a6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b8bd43820a6, replyNumber=0, likeNumber=42, createdTime=2015-09-20, rootId=0, userName=meichuangyi, userId=ab3732554119, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b8bd43820a6, moduleTitle=NEJM：卡非佐米+来那度胺+地塞米松治疗复发性多发性骨髓瘤：风险or受益？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b8bd43820a6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1718335, encodeId=b9871e1833592, content=<a href='/topic/show?id=5a014253400' target=_blank style='color:#2F92EE;'>#复发性多发性骨髓瘤#</a>, objectTitle=FDA批准帕比司他用于复发性多发性骨髓瘤的治疗, objectType=article, longId=47420, objectId=3cb54e420f6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3cb54e420f6, replyNumber=0, likeNumber=32, createdTime=2015-09-20, rootId=0, userName=meichuangyi, userId=ab3732554119, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3cb54e420f6, moduleTitle=FDA批准帕比司他用于复发性多发性骨髓瘤的治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3cb54e420f6)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

复发性多发性骨髓瘤

2020-05-29

meichuangyi (审核中...)

前往app查看评论内容

#复发性多发性骨髓瘤#

Haematologica：Isatuximab 加卡非佐米和地塞米松与卡非佐米和地塞米松在肾功能不全的复发性多发性骨髓瘤患者中的比较

2022-08-04

meichuangyi (审核中...)

前往app查看评论内容

#复发性多发性骨髓瘤#

NEJM：Ide-cel治疗复发性多发性骨髓瘤患者II期临床获得成功

2021-07-15

meichuangyi (审核中...)

前往app查看评论内容

#复发性多发性骨髓瘤#

CHMP建议批准Sarclisa（isatuximab）与卡非佐米和地塞米松联合治疗复发性多发性骨髓瘤

2022-02-02

meichuangyi (审核中...)

前往app查看评论内容

#复发性多发性骨髓瘤#

Blood：pomalidomide、bortezomib和dexamethasone联合治疗复发性多发性骨髓瘤的很大耐受剂量、疗效和安全性。

2018-05-15

meichuangyi (审核中...)

前往app查看评论内容

#复发性多发性骨髓瘤#

专家解读：国际骨髓瘤工作组复发性多发性骨髓瘤处理推荐

2016-12-11

meichuangyi (审核中...)

前往app查看评论内容

#复发性多发性骨髓瘤#

Lancet Haematology：复发性多发性骨髓瘤：Elotuzumab有良好的安全性和疗效性

2016-10-09

meichuangyi (审核中...)

前往app查看评论内容

#复发性多发性骨髓瘤#

NEJM：卡非佐米+来那度胺+地塞米松治疗复发性多发性骨髓瘤：风险or受益？

2015-09-20

meichuangyi (审核中...)

前往app查看评论内容

#复发性多发性骨髓瘤#

FDA批准帕比司他用于复发性多发性骨髓瘤的治疗

2015-09-20

科室
- - 订阅+
  - 更多科室
工具
服务